{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:27:18Z","timestamp":1762954038754,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-20-147, BCRF-21-147, BCRF-22-147"],"award-info":[{"award-number":["BCRF-20-147, BCRF-21-147, BCRF-22-147"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RICBAC Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-024-01943-1","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T14:41:02Z","timestamp":1734532862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ERBB2\/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers"],"prefix":"10.1186","volume":"26","author":[{"given":"Irene Rin","family":"Mitsiades","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maristela","family":"Onozato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. John","family":"Iafrate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do\u011fa C.","family":"G\u00fclhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis C.","family":"Sgroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Rheinbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"11","key":"1943_CR1","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","volume":"30","author":"JMS Bartlett","year":"2019","unstructured":"Bartlett JMS, Sgroi DC, Treuner K, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant Tamoxifen-To offer more? (aTTom) trial. Ann Oncol. 2019;30(11):1776\u201383.","journal-title":"Ann Oncol"},{"key":"1943_CR2","doi-asserted-by":"crossref","unstructured":"Bartlett JMS, Sgroi DC, Treuner K, et al. Breast Cancer Index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the Trans-aTTom study. Clin Cancer Res. 2022;28(9):1871\u201380.","DOI":"10.1158\/1078-0432.CCR-21-3385"},{"issue":"14","key":"1943_CR3","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/jnci\/djt146","volume":"105","author":"DC Sgroi","year":"2013","unstructured":"Sgroi DC, Carney E, Zarrella E, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13\/IL17BR biomarker. J Natl Cancer Inst. 2013;105(14):1036\u201342.","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"1943_CR4","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-13-0804","volume":"19","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Schnabel CA, Schroeder BE, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013;19(15):4196\u2013205.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1943_CR5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S1470-2045(13)70387-5","volume":"14","author":"DC Sgroi","year":"2013","unstructured":"Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;14(11):1067\u201376.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1943_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/1078-0432.CCR-20-2737","volume":"27","author":"I Noordhoek","year":"2021","unstructured":"Noordhoek I, Treuner K, Putter H, et al. Breast Cancer Index predicts extended Endocrine Benefit to individualize selection of patients with HR(+) early-stage breast Cancer for 10 years of endocrine therapy. Clin Cancer Res. 2021;27(1):311\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1943_CR7","first-page":"PS17","volume":"81","author":"KS Treuner","year":"2021","unstructured":"Treuner KS, Schnabel D, Benner C, Heinz C. Characterization of HOXB13-induced estrogen receptor reprogramming in breast cancer cells. Cancer Res. 2021;81(4):PS17\u201332.","journal-title":"Cancer Res"},{"issue":"21","key":"1943_CR8","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1158\/1078-0432.CCR-07-0310","volume":"13","author":"Z Wang","year":"2007","unstructured":"Wang Z, Dahiya S, Provencher H, et al. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clin Cancer Res. 2007;13(21):6327\u201334.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1943_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/dvdy.24075","volume":"243","author":"N Cerda-Esteban","year":"2014","unstructured":"Cerda-Esteban N, Spagnoli FM. Glimpse into hox and tale regulation of cell differentiation and reprogramming. Dev Dyn. 2014;243(1):76\u201387.","journal-title":"Dev Dyn"},{"issue":"3","key":"1943_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1210\/en.2006-1250","volume":"148","author":"L Huang","year":"2007","unstructured":"Huang L, Pu Y, Hepps D, Danielpour D, Prins GS. Posterior hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Endocrinology. 2007;148(3):1235\u201345.","journal-title":"Endocrinology"},{"issue":"10","key":"1943_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nrc907","volume":"2","author":"C Abate-Shen","year":"2002","unstructured":"Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer. 2002;2(10):777\u201385.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1943_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.gendis.2017.01.003","volume":"4","author":"H Brechka","year":"2017","unstructured":"Brechka H, Bhanvadia RR, VanOpstall C, Vander Griend DJ. HOXB13 mutations and binding partners in prostate development and cancer: function, clinical significance, and future directions. Genes Dis. 2017;4(2):75\u201387.","journal-title":"Genes Dis"},{"issue":"5","key":"1943_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1349-7006.2003.tb01461.x","volume":"94","author":"YC Hung","year":"2003","unstructured":"Hung YC, Ueda M, Terai Y, et al. Homeobox gene expression and mutation in cervical carcinoma cells. Cancer Sci. 2003;94(5):437\u201341.","journal-title":"Cancer Sci"},{"issue":"3","key":"1943_CR14","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/ijgc-00009577-200605000-00051","volume":"16","author":"R Lopez","year":"2006","unstructured":"Lopez R, Garrido E, Vazquez G, et al. A subgroup of HOX Abd-B gene is differentially expressed in cervical cancer. Int J Gynecol Cancer. 2006;16(3):1289\u201396.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"1943_CR15","first-page":"931","volume":"28","author":"T Yamashita","year":"2006","unstructured":"Yamashita T, Tazawa S, Yawei Z, et al. Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells. Int J Oncol. 2006;28(4):931\u20138.","journal-title":"Int J Oncol"},{"issue":"4","key":"1943_CR16","first-page":"721","volume":"13","author":"Y Zhao","year":"2005","unstructured":"Zhao Y, Yamashita T, Ishikawa M. Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer. Oncol Rep. 2005;13(4):721\u20136.","journal-title":"Oncol Rep"},{"issue":"43","key":"1943_CR17","doi-asserted-by":"publisher","first-page":"17093","DOI":"10.1073\/pnas.0707938104","volume":"104","author":"J Miao","year":"2007","unstructured":"Miao J, Wang Z, Provencher H, et al. HOXB13 promotes ovarian cancer progression. Proc Natl Acad Sci U S A. 2007;104(43):17093\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1943_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1210\/er.2006-0045","volume":"29","author":"G Arpino","year":"2008","unstructured":"Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29(2):217\u201333.","journal-title":"Endocr Rev"},{"issue":"11","key":"1943_CR19","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/annonc\/mdt287","volume":"24","author":"F Montemurro","year":"2013","unstructured":"Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013;24(11):2715\u201324.","journal-title":"Ann Oncol"},{"issue":"20","key":"1943_CR20","first-page":"5887","volume":"60","author":"H Kurokawa","year":"2000","unstructured":"Kurokawa H, Lenferink AE, Simpson JF, et al. Inhibition of HER2\/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000;60(20):5887\u201394.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"1943_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00280-005-0108-2","volume":"56","author":"R Schiff","year":"2005","unstructured":"Schiff R, Massarweh SA, Shou J, et al. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005;56(Suppl 1):10\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16","key":"1943_CR22","doi-asserted-by":"publisher","first-page":"8266","DOI":"10.1158\/0008-5472.CAN-05-4045","volume":"66","author":"S Massarweh","year":"2006","unstructured":"Massarweh S, Osborne CK, Jiang S, et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2\/neu-positive breast cancer. Cancer Res. 2006;66(16):8266\u201373.","journal-title":"Cancer Res"},{"key":"1943_CR23","doi-asserted-by":"crossref","unstructured":"Montaser RZ, Coley HM. Crosstalk between ERalpha and receptor tyrosine kinase signalling and implications for the development of Anti-endocrine Resistance. Cancers (Basel) 2018; 10(6).","DOI":"10.3390\/cancers10060209"},{"issue":"4","key":"1943_CR24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor AM, Shih J, Ha G, et al. Genomic and functional approaches to understanding Cancer Aneuploidy. Cancer Cell. 2018;33(4):676\u201389. e3.","journal-title":"Cancer Cell"},{"issue":"7661","key":"1943_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature22992","volume":"547","author":"E Rheinbay","year":"2017","unstructured":"Rheinbay E, Parasuraman P, Grimsby J, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017;547(7661):55\u201360.","journal-title":"Nature"},{"issue":"7403","key":"1943_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346\u201352.","journal-title":"Nature"},{"issue":"7757","key":"1943_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jan\u00e9-Valbuena J, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569(7757):503\u20138.","journal-title":"Nature"},{"issue":"10","key":"1943_CR28","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/ng.3934","volume":"49","author":"P Polak","year":"2017","unstructured":"Polak P, Kim J, Braunstein LZ, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017;49(10):1476\u201386.","journal-title":"Nat Genet"},{"issue":"5","key":"1943_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","volume":"51","author":"DC Gulhan","year":"2019","unstructured":"Gulhan DC, Lee JJ, Melloni GEM, Cortes-Ciriano I, Park PJ. Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nat Genet. 2019;51(5):912\u20139.","journal-title":"Nat Genet"},{"key":"1943_CR30","unstructured":"Thorsson V, Gibbs DL, Brown SD et al. The Immune Landscape of Cancer. Immunity 2018; 48(4): 812\u2009\u2013\u200930 e14."},{"issue":"7","key":"1943_CR31","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/modpathol.3880127","volume":"13","author":"S Kamoshida","year":"2000","unstructured":"Kamoshida S, Ogane N, Yasuda M, et al. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas. Mod Pathol. 2000;13(7):736\u201341.","journal-title":"Mod Pathol"},{"issue":"12","key":"1943_CR32","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast Cancer: ASCO\/CAP Guideline Update. J Clin Oncol. 2020;38(12):1346\u201366.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1943_CR33","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867\u201372.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1943_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, et al. An Integrated TCGA Pan-cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018;173(2):400\u201316. e11.","journal-title":"Cell"},{"issue":"60","key":"1943_CR35","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","volume":"6","author":"ML Waskom","year":"2021","unstructured":"Waskom ML. Seaborn: statistical data visualization. J Open Source Softw. 2021;6(60):3021.","journal-title":"J Open Source Softw"},{"issue":"03","key":"1943_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter JD, Matplotlib. A 2D graphics environment. Comput Sci Eng. 2007;9(03):90\u20135.","journal-title":"Comput Sci Eng"},{"issue":"9","key":"1943_CR37","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1101\/gr.092759.109","volume":"19","author":"M Krzywinski","year":"2009","unstructured":"Krzywinski M, Schein J, Birol I, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639\u201345.","journal-title":"Genome Res"},{"issue":"7418","key":"1943_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"1","key":"1943_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12920-020-0729-7","volume":"13","author":"CL Lin","year":"2020","unstructured":"Lin CL, Tan X, Chen M, et al. ERalpha-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer. BMC Med Genomics. 2020;13(1):69.","journal-title":"BMC Med Genomics"},{"issue":"3","key":"1943_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","volume":"52","author":"I Cortes-Ciriano","year":"2020","unstructured":"Cortes-Ciriano I, Lee JJ, Xi R, et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2020;52(3):331\u201341.","journal-title":"Nat Genet"},{"key":"1943_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1471-2164-15-82","volume":"15","author":"H Cai","year":"2014","unstructured":"Cai H, Kumar N, Bagheri HC, von Mering C, Robinson MD, Baudis M. Chromothripsis-like patterns are recurring but heterogeneously distributed features in a survey of 22,347 cancer genome screens. BMC Genomics. 2014;15:82.","journal-title":"BMC Genomics"},{"issue":"4","key":"1943_CR42","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.","journal-title":"Genome Biol"},{"issue":"10","key":"1943_CR43","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1101\/gr.164871.113","volume":"24","author":"K Inaki","year":"2014","unstructured":"Inaki K, Menghi F, Woo XY, et al. Systems consequences of amplicon formation in human breast cancer. Genome Res. 2014;24(10):1559\u201371.","journal-title":"Genome Res"},{"issue":"9","key":"1943_CR44","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","volume":"52","author":"H Kim","year":"2020","unstructured":"Kim H, Nguyen NP, Turner K, et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat Genet. 2020;52(9):891\u20137.","journal-title":"Nat Genet"},{"issue":"1","key":"1943_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cell.2020.08.006","volume":"183","author":"K Hadi","year":"2020","unstructured":"Hadi K, Yao X, Behr JM, et al. Distinct classes of Complex Structural Variation uncovered across thousands of Cancer Genome Graphs. Cell. 2020;183(1):197\u2013210. e32.","journal-title":"Cell"},{"issue":"1","key":"1943_CR46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/1471-2164-15-579","volume":"15","author":"E Przybytkowski","year":"2014","unstructured":"Przybytkowski E, Lenkiewicz E, Barrett MT, et al. Chromosome-breakage genomic instability and chromothripsis in breast cancer. BMC Genomics. 2014;15(1):579.","journal-title":"BMC Genomics"},{"issue":"6","key":"1943_CR47","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703\u201313.","journal-title":"Nat Med"},{"issue":"16","key":"1943_CR48","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.7150\/jca.18457","volume":"8","author":"X Dai","year":"2017","unstructured":"Dai X, Cheng H, Bai Z, Li J. Breast Cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017;8(16):3131\u201341.","journal-title":"J Cancer"},{"issue":"9","key":"1943_CR49","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","volume":"45","author":"SA Roberts","year":"2013","unstructured":"Roberts SA, Lawrence MS, Klimczak LJ, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45(9):970\u20136.","journal-title":"Nat Genet"},{"issue":"7916","key":"1943_CR50","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","volume":"606","author":"CD Steele","year":"2022","unstructured":"Steele CD, Abbasi A, Islam SMA, et al. Signatures of copy number alterations in human cancer. Nature. 2022;606(7916):984\u201391.","journal-title":"Nature"},{"issue":"7793","key":"1943_CR51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94\u2013101.","journal-title":"Nature"},{"issue":"7463","key":"1943_CR52","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature"},{"issue":"1","key":"1943_CR53","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.1038\/s41467-020-20173-5","volume":"11","author":"JW Pan","year":"2020","unstructured":"Pan JW, Zabidi MMA, Ng PS, et al. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nat Commun. 2020;11(1):6433.","journal-title":"Nat Commun"},{"issue":"1","key":"1943_CR54","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41467-018-04129-4","volume":"9","author":"Z Kan","year":"2018","unstructured":"Kan Z, Ding Y, Kim J, et al. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat Commun. 2018;9(1):1725.","journal-title":"Nat Commun"},{"issue":"28","key":"1943_CR55","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1200\/JCO.2006.06.6944","volume":"24","author":"XJ Ma","year":"2006","unstructured":"Ma XJ, Hilsenbeck SG, Wang W, et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006;24(28):4611\u20139.","journal-title":"J Clin Oncol"},{"issue":"7793","key":"1943_CR56","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1913-9","volume":"578","author":"Y Li","year":"2020","unstructured":"Li Y, Roberts ND, Wala JA, et al. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578(7793):112\u201321.","journal-title":"Nature"},{"issue":"2","key":"1943_CR57","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/bib\/bbs017","volume":"14","author":"H Thorvaldsdottir","year":"2013","unstructured":"Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14(2):178\u201392.","journal-title":"Brief Bioinform"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01943-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-024-01943-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01943-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T15:15:46Z","timestamp":1734534946000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-024-01943-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1186\/s13058-024-01943-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"type":"electronic","value":"1465-542X"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Massachusetts General Hospital IRB under protocol 2002-P002059\/MGH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}